

Regd. & Corp. Office:  
1506, Chiranjiv Tower,  
43, Nehru Place,  
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),  
E-mail: info@medicamen.com  
Web: www.medicamen.com  
CIN No.: L74899DL1993PLC056594

Ref: STEX/Results/Published-2021-22

Date: 10.02.2022

BSE Limited  
Department of Corporate Services-Listing  
PJ Towers, Dalal Street  
Mumbai- 400001

National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra(E) Mumbai – 400051

Scrip Code: 531146

Symbol: MEDICAMEQ

Company Number: 531146

Sub. : Copy of Publication for Un-audited Financial Results for the quarter and nine months ended December 31, 2021

Dear Sir,

Pursuant to regulation 30 & 47 of SEBI (Listing obligation and disclosure requirements) Regulations, 2015 ("the Regulations"), please find enclosed herewith the Un-audited Financial Results of the Company for the quarter and nine months ended on December 31, 2021 approved by the Board of Directors at their Meeting held on 08.02.2022.



The copy of the results published in the Financial Express and Jansatta dated February 10, 2022 is enclosed.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking You,

Yours truly,  
For Medicamen Biotech Limited



Parul Choudhary  
Company Secretary  
ACS-44157

Encl: As above.



## MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019  
CIN: L74899DL 1993PLC056594 E-mail: cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Un-audited Financial Results for the nine months ended on 31.12.2021 (Rupees In Lakhs) except per share data

Sl. No.	Particulars	Standalone						Consolidated						
		Quarter Ended			Nine months ended			Quarter Ended			Nine months ended			Year Ended
		Un-audited 31.12.2021	Un-audited 30.09.2021	Un-audited 31.12.2020	Un-audited 31.12.2021	Un-audited 31.12.2020	Audited 31.03.2021	Un-audited 31.12.2021	Un-audited 30.09.2021	Un-audited 31.12.2020	Un-audited 31.12.2021	Un-audited 31.12.2020	Audited 31.03.2021	
1	Total income from operations (net)	3346.84	3299.65	3292.28	9407.39	9002.59	11090.06	3346.84	3299.65	3292.28	9407.39	9169.41	11347.01	
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	507.61	505.32	445.48	1487.51	1210.77	1675.12	507.61	505.32	445.48	1487.51	1229.33	1639.40	
3	Net Profit/(Loss) for the period before tax (after exceptional and/or Extraordinary items)	507.61	505.32	445.48	1487.51	1210.77	1675.12	507.61	505.32	445.48	1487.51	1229.33	1639.40	
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	377.85	422.18	301.47	1215.17	834.32	1248.66	377.85	422.18	301.47	1215.17	848.25	1212.94	
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	377.85	422.18	301.47	1215.17	834.32	1248.66	377.85	422.18	301.47	1215.17	848.25	1212.94	
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)													
8	Earnings Per Share (of Rs.5/- each) (for continuing and discontinued operation)													
	Basic:	3.09	3.46	2.47	9.95	6.83	10.22	3.09	3.46	2.47	9.95	6.94	9.93	
	Diluted:	3.09	3.46	2.47	9.95	6.83	10.22	3.09	3.46	2.47	9.95	6.94	9.93	

### Note:

- The Un-audited financial results for the quarter and nine months ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 8th February 2022.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable.
- \* The other expenses include Rs. 2.50 Cr in respect of Oncology formulation plant at Haridwar which is under Product validation stage.
- The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 - "Earning per Share"
- Limited Review report has been carried out by the Statutory Auditors for the above period.
- The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place: New Delhi  
Date : 08.02.2022

For Medicamen Biotech Limited  
Sd/-  
Rahul Bishnoi  
Chairman

### LYKIS LIMITED

CIN: L74999WB1984PLC038064

Registered Office: 57B, C.R. Avenue, 1st Floor, Kolkata 700 012

Tel: +91 22 4069 4069 Fax: +91 22 3009 8128

E-mail: cs@lykis.in Website: www.lykis.in

### PUBLIC NOTICE TO THE SHAREHOLDERS OF LYKIS LIMITED

This public announcement is being made in compliance with Regulation 6(c) of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021 (hereinafter referred to as 'Delisting Regulations') to the shareholders of the Company in respect of voluntary delisting of equity shares of the Company from 'The Calcutta Stock Exchange Limited' ('CSE'). At present the shares of the Company are listed on both the recognized stock exchanges i.e. BSE Limited and CSE. The Board of Directors has, in its meeting held on Monday, February 07, 2022, approved delisting of shares of the Company from CSE due to the decrease in overall trade volume in the shares of the Company and to curb the fixed cost incurred by the company.

The shares of the Company shall continue to remain listed on BSE Limited, which is a recognized stock exchange having nationwide trading terminal.

In case the shareholders have any query or objection in pursuant to this notice, they can email the same on cs@lykis.in or send their written query or objection to 57B, C.R. Avenue, 1st Floor, Kolkata 700 012.

For and on behalf of Lykis Limited

### ANY LIMITED

Kolkata-700 001

Website : www.gillandersarbutnot.com

THS ENDED 31ST DECEMBER 2021

(₹ in Lakhs)

### CONSOLIDATED

Quarter Ended			Nine Months Ended		Year Ended
30-Sep-21	31-Dec-20	31-Dec-21	31-Dec-20	31-Mar-21	

सम्पत्ति नं० 2. बंधक सम्पत्ति स्थित नं० 178/4 (नया नं० 314/3/178/1) स्थित लखी बाग देहरादून, कुल क्षेत्र 36 वर्ग मीटर (विक्रेय विलेख सब-रजिस्ट्रार ऑफिस देहरादून बुक नं० 1, वॉल्यूम नं० 498, पेज नं० 47 इसके अतिरिक्त बुक नं० 1, वॉल्यूम 157, पेज नं० 617-636, क्र०स० 3340, दिनांक 31.08.1998 पर पंजीकृत है। सीमाएं:- नाली के बाद रास्ता एवं नाला, पश्चिम: श्री रघुवीर सिंह की सम्पत्ति, उत्तर: आम दीवार एवं श्रीमती गुरुदीन कौर की सम्पत्ति, दक्षिण: आम दीवार एवं श्री भुवन चन्द पांडेय की सम्पत्ति। सम्पत्ति स्वामी श्री मदन लाल पुत्र श्री अमर चंद।

हैं, और जो मौजा पलवल राम नगर, अघ नगर, परिषद, स्थित है।

दिनांक: 08.02.2022

स्थान - देहरादून

प्राधिकृत अधिकारी, पंजाब नेशनल बैंक

दिनांक: 08.02.2022

स्थान: साहिबाबाद



# MEDICAMEN BIOTECH LTD.

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019  
CIN: L74899DL 1993PLC056594 E-mail: cs@medicamen.com, www.medicamen.com

Extracts of Standalone and Consolidated Un-audited Financial Results for the nine months ended on 31.12.2021 (Rupees in Lakhs) except per share data

Sl. No.	Particulars	Standalone						Consolidated					
		Quarter Ended			Nine months ended			Quarter Ended			Nine months ended		
		Un-audited 31.12.2021	Un-audited 30.09.2021	Un-audited 31.12.2020	Un-audited 31.12.2021	Un-audited 31.12.2020	Audited 31.03.2021	Un-audited 31.12.2021	Un-audited 30.09.2021	Un-audited 31.12.2020	Un-audited 31.12.2021	Un-audited 31.12.2020	Audited 31.03.2021
1	Total income from operations (net)	3346.84	3299.65	3292.28	9407.39	9002.59	11090.06	3346.84	3299.65	3292.28	9407.39	9169.41	11347.01
2	Net Profit/(Loss) for the period (before tax, exceptional and/or Extraordinary items)	507.61	505.32	445.48	1487.51	1210.77	1675.12	507.61	505.32	445.48	1487.51	1229.33	1639.40
3	Net Profit/(Loss) for the period before tax (after exceptional and/ or Extraordinary items)	507.61	505.32	445.48	1487.51	1210.77	1675.12	507.61	505.32	445.48	1487.51	1229.33	1639.40
4	Net Profit/(Loss) for the period after tax (after exceptional and/or Extraordinary items)	377.85	422.18	301.47	1215.17	834.32	1248.66	377.85	422.18	301.47	1215.17	848.25	1212.94
5	Total comprehensive income for the period (Comprising Profit/(loss) for the period (after tax) and other Comprehensive income (after tax))	377.85	422.18	301.47	1215.17	834.32	1248.66	377.85	422.18	301.47	1215.17	848.25	1212.94
6	Equity Share Capital	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66	1221.66
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year)												
8	Earnings Per Share (of Rs.5/- each) (for continuing and discontinued operation)												
	Basic:	3.09	3.46	2.47	9.95	6.83	10.22	3.09	3.46	2.47	9.95	6.94	9.93
	Diluted:	3.09	3.46	2.47	9.95	6.83	10.22	3.09	3.46	2.47	9.95	6.94	9.93

- Note:**
- The Un-audited financial results for the quarter and nine months ended have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 8th February 2022.
  - This statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
  - The company operates only in one business segment, viz. Pharmaceuticals formulations, hence segment reporting is not applicable
  - \* The other expenses include Rs. 2.50 Cr in respect of Oncology formulation plant at Haridwar which is under Product validation stage.
  - The Earning Per Share has been calculated as per Indian Accounting Standard (Ind AS) 33 "Earning per Share"
  - Limited Review report has been carried out by the Statutory Auditors for the above period.
  - The figures are regrouped in previous year also, wherever considered necessary, to make them comparable.

Place: New Delhi  
Date : 08.02.2022

For Medicamen Biotech Limited  
Sd/-  
Rahul Bishnoi  
Chairman

निविदा सं. आरसी/रेलटेल/उत्तरांचल/फिरोजपुर/खंड में पांच कथुंगल, जे इलेक्ट्रॉनिक से मानक-II के संबंध बोलीदाताओं जाती हैं। निविदा दस्तावेज व वेब परिशिष्ट/इ अपलोड किए

प्रपत्र सं राष्ट्रीय कंपनी नई दिल्ली

सेफेरो गोल्ड इ वैसिलॉट एक्स लिमिटेड के स की धारा 230 गोविन्द रिशो इ उक आवेदन प फोट के समक्ष गई थी, देश स्थिति के कारण अगली सुनवाई आवेदन का व्यक्ति उनके अधिका हा आवेदन के वह आवेदन से कम दो दिन जाये। यदि सूचना के सा प्रति प्रस्तुत क पर उसे प्राप्त अयोहस्ताक्षरी जायेगी। तिथि: 08.02.